HRP20130920T1 - Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival - Google Patents

Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival Download PDF

Info

Publication number
HRP20130920T1
HRP20130920T1 HRP20130920AT HRP20130920T HRP20130920T1 HR P20130920 T1 HRP20130920 T1 HR P20130920T1 HR P20130920A T HRP20130920A T HR P20130920AT HR P20130920 T HRP20130920 T HR P20130920T HR P20130920 T1 HRP20130920 T1 HR P20130920T1
Authority
HR
Croatia
Prior art keywords
methods
tolvaptan
chemotherapy agents
improve survival
vasopressin antagonists
Prior art date
Application number
HRP20130920AT
Other languages
Croatian (hr)
Inventor
Yongge Liu
Junichi Kambayashi
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20130920T1 publication Critical patent/HRP20130920T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Claims (4)

1. Tolvaptan ili njegova farmaceutski prihvatljiva sol za uporabu u postupku smanjenja kardiotoksičnosti i/ili poboljšanja stope preživljavanja nakon kemoterapije doksorubicinom, naznačen time, da se tolvaptan ili njegova farmaceutski prihvatljiva sol primjenjuje istodobno, ili prije primjene doksorubicina.1. Tolvaptan or its pharmaceutically acceptable salt for use in the process of reducing cardiotoxicity and/or improving the survival rate after doxorubicin chemotherapy, characterized in that tolvaptan or its pharmaceutically acceptable salt is administered simultaneously, or before doxorubicin administration. 2. Tolvaptan prema zahtjevu 1, naznačen time, da se upotrebljava u postupku smanjivanja kardiotoksičnosti.2. Tolvaptan according to claim 1, characterized in that it is used in the process of reducing cardiotoxicity. 3. Tolvaptan prema zahtjevu 1, naznačen time, se upotrebljava u postupku za poboljšanje stope preživljavanja.3. Tolvaptan according to claim 1, characterized in that it is used in a process for improving the survival rate. 4. Farmaceutski pripravak koji sadržava tolvaptan ili njegovu farmaceutski prihvatljivu sol, naznačen time, da se upotrebljava u postupku smanjenja kardiotoksičnosti i/ili poboljšanja stope preživljavanja pri kemoterapiji doksorubicinom, pri čemu se tolvaptan ili njegova farmaceutski prihvatljiva sol primjenjuje istodobno, ili prije primjene doksorubicina.4. A pharmaceutical preparation containing tolvaptan or its pharmaceutically acceptable salt, indicated in that it is used in the process of reducing cardiotoxicity and/or improving the survival rate during chemotherapy with doxorubicin, whereby tolvaptan or its pharmaceutically acceptable salt is administered simultaneously, or before the administration of doxorubicin.
HRP20130920AT 2007-05-15 2013-09-27 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival HRP20130920T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93808907P 2007-05-15 2007-05-15
PCT/US2008/063374 WO2008144269A2 (en) 2007-05-15 2008-05-12 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Publications (1)

Publication Number Publication Date
HRP20130920T1 true HRP20130920T1 (en) 2013-11-08

Family

ID=40122254

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130920AT HRP20130920T1 (en) 2007-05-15 2013-09-27 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Country Status (25)

Country Link
US (1) US8372830B2 (en)
EP (1) EP2146721B1 (en)
KR (1) KR101508797B1 (en)
CN (2) CN101808517A (en)
AR (1) AR066544A1 (en)
AU (1) AU2008254273B2 (en)
BR (1) BRPI0811134A2 (en)
CA (1) CA2685186A1 (en)
CO (1) CO6280574A2 (en)
CY (1) CY1114163T1 (en)
DK (1) DK2146721T3 (en)
ES (1) ES2421639T3 (en)
HK (2) HK1138772A1 (en)
HR (1) HRP20130920T1 (en)
IL (1) IL202094A (en)
MX (1) MX2009012164A (en)
MY (1) MY150682A (en)
NZ (1) NZ581126A (en)
PL (1) PL2146721T3 (en)
PT (1) PT2146721E (en)
RU (1) RU2470643C2 (en)
SI (1) SI2146721T1 (en)
TW (1) TWI428131B (en)
UA (1) UA99914C2 (en)
WO (1) WO2008144269A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503085A (en) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Combined therapy including angiotensin converting enzyme inhibitor and vasopressin receptor antagonist
WO2013176955A1 (en) * 2012-05-21 2013-11-28 The General Hospital Corporation Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
JP6542192B2 (en) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． BMP inhibitors and methods of use thereof
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
CN109311959A (en) 2016-01-04 2019-02-05 艾得佩索拉公司 Peptide analogues
US11701409B2 (en) 2016-02-09 2023-07-18 Adepthera Llc Dosing and use of long-acting CLR/ramp agonists
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
EP3645031A4 (en) 2017-06-30 2021-03-31 Adepthera LLC Peptide analogs
TWI737974B (en) 2018-04-09 2021-09-01 美商標徑製藥公司 Dosing regimens for treatment of proliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
ES2421639T3 (en) 2013-09-04
AU2008254273A1 (en) 2008-11-27
AR066544A1 (en) 2009-08-26
TWI428131B (en) 2014-03-01
US8372830B2 (en) 2013-02-12
EP2146721A4 (en) 2010-08-25
EP2146721B1 (en) 2013-07-10
UA99914C2 (en) 2012-10-25
HK1138772A1 (en) 2010-09-03
CY1114163T1 (en) 2016-08-31
TW200916104A (en) 2009-04-16
EP2146721A2 (en) 2010-01-27
KR101508797B1 (en) 2015-04-06
PL2146721T3 (en) 2013-12-31
CA2685186A1 (en) 2008-11-27
IL202094A (en) 2015-06-30
AU2008254273B2 (en) 2013-03-28
CO6280574A2 (en) 2011-05-20
SI2146721T1 (en) 2013-10-30
RU2009146376A (en) 2011-06-20
BRPI0811134A2 (en) 2014-09-30
RU2470643C2 (en) 2012-12-27
CN103550233A (en) 2014-02-05
MX2009012164A (en) 2009-12-09
WO2008144269A2 (en) 2008-11-27
KR20100019439A (en) 2010-02-18
DK2146721T3 (en) 2013-07-22
IL202094A0 (en) 2010-06-16
HK1176318A1 (en) 2013-07-26
WO2008144269A3 (en) 2010-01-21
US20100249104A1 (en) 2010-09-30
NZ581126A (en) 2012-04-27
MY150682A (en) 2014-02-28
PT2146721E (en) 2013-07-18
CN101808517A (en) 2010-08-18

Similar Documents

Publication Publication Date Title
HRP20130920T1 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AR086391A1 (en) INTRANASAL PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE NALOXONE
MX2010003923A (en) Pharmaceutical formulation of valsartan.
JP2010525050A5 (en)
JP2016501828A5 (en)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
TW200603787A (en) Topical preparations containing ambroxol
BR112012003283A2 (en) pharmaceutically acceptable salt of an amphiphilic photosensitizing agent, pharmaceutical composition, product, kit, use of a pharmaceutically acceptable salt of an amphiphilic photosensitizing agent, and method of introducing a drug molecule into the cytosol of a cell in a patient.
ATE494889T1 (en) PHARMACEUTICAL COMBINATION WITH 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL AND PARACETAMOL
RS52457B (en) Powder formulation for valganciclovir
CL2011003046A1 (en) Pharmaceutical composition comprising 7- (2,5-dihydro-4-imidazo [1,2-a] -pyridin-3-yl-2,5-dioxo-1h-pyrrol-3-yl) -9-fluoro-1 , 2,3,4-tetrahydro-2- (1-piperidinyl-carbonyl) pyrrolo [3,2,1-jk] [1,4] benzodiazepine, a salt or solvate, sbe7-b-cd and optionally a buffer; Preparation process; Useful to treat cancer (div. sol. 1848-08).
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
CA2744339A1 (en) Method for treating parkinson's disease
Sharma et al. Permeation enhancers in the transmucosal delivery of macromolecules
UA93365C2 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof
PE20090625A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE
HRP20201475T1 (en) Use of neridronic acid or of its salt for the treatment of osteoarthrosis
CO2019013645A2 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
RU2010145723A (en) METHOD FOR TREATMENT OF CHRONIC REMAINING ATPHOSIC STOMATITIS AND MEANS FOR ITS IMPLEMENTATION
ITMI20070817A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING L-CARNITINE AND AN ANTAGONIST AGENT OF MEMBRANE ADENOSIN RECEPTORS, THEIR DERIVATIVES AND / OR PHARMACEUTICALLY ACCEPTABLE SALTS, AND USE OF THE SAME IN THE PREPARATION OF DRUGS WITH NON-TOXIC EFFECT OF INIBI
PL1877035T3 (en) Pharmaceutical composition and dosage form fast-disintegrating in the mouth , and process to prepare it
ATE551998T1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING TAMSULOSINE
CR7426A (en) USE OF THE ANTITUMOR INDOLOPIRROLOCARBAZOL DERIVATIVE AND ANOTHER ANTI-BANERIGEN AGENT IN COMBINATION